AU2013245989B2 - Bis-polymer lipid-peptide conjugates and nanoparticles thereof - Google Patents

Bis-polymer lipid-peptide conjugates and nanoparticles thereof Download PDF

Info

Publication number
AU2013245989B2
AU2013245989B2 AU2013245989A AU2013245989A AU2013245989B2 AU 2013245989 B2 AU2013245989 B2 AU 2013245989B2 AU 2013245989 A AU2013245989 A AU 2013245989A AU 2013245989 A AU2013245989 A AU 2013245989A AU 2013245989 B2 AU2013245989 B2 AU 2013245989B2
Authority
AU
Australia
Prior art keywords
polymer
peptide
micelles
conjugate
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013245989A
Other languages
English (en)
Other versions
AU2013245989A1 (en
Inventor
He Dong
Nikhil DUBE
Jessica Shu
Ting Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2013245989A1 publication Critical patent/AU2013245989A1/en
Application granted granted Critical
Publication of AU2013245989B2 publication Critical patent/AU2013245989B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
AU2013245989A 2012-04-10 2013-04-10 Bis-polymer lipid-peptide conjugates and nanoparticles thereof Ceased AU2013245989B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261622330P 2012-04-10 2012-04-10
US61/622,330 2012-04-10
US201261668923P 2012-07-06 2012-07-06
US61/668,923 2012-07-06
PCT/US2013/035924 WO2013155152A1 (en) 2012-04-10 2013-04-10 Bis-polymer lipid-peptide conjugates and nanoparticles thereof

Publications (2)

Publication Number Publication Date
AU2013245989A1 AU2013245989A1 (en) 2014-10-30
AU2013245989B2 true AU2013245989B2 (en) 2017-03-30

Family

ID=49328119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013245989A Ceased AU2013245989B2 (en) 2012-04-10 2013-04-10 Bis-polymer lipid-peptide conjugates and nanoparticles thereof

Country Status (11)

Country Link
EP (1) EP2841083B1 (enExample)
JP (2) JP6426600B2 (enExample)
KR (1) KR20140143838A (enExample)
CN (1) CN104379158A (enExample)
AU (1) AU2013245989B2 (enExample)
CA (1) CA2869984C (enExample)
IL (1) IL235167A0 (enExample)
IN (1) IN2014DN08781A (enExample)
MX (1) MX2014012271A (enExample)
RU (1) RU2014144945A (enExample)
WO (1) WO2013155152A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
WO2016136641A1 (ja) * 2015-02-23 2016-09-01 日本化薬株式会社 生理活性物質結合ブロック共重合体
US10449259B2 (en) 2015-10-02 2019-10-22 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof
EP3863609A4 (en) * 2018-10-12 2022-11-16 University of Pittsburgh - Of the Commonwealth System of Higher Education SMALL POLYMERIC CARRIERS FOR DELIVERY OF ACTIVE INGREDIENTS
WO2024260311A1 (zh) * 2023-06-19 2024-12-26 华南理工大学 基于序列固定聚赖氨酸的pH敏感膜裂解材料及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110200527A1 (en) * 2007-11-05 2011-08-18 Shanghai Jiaotong University Peptide Ligand Directed Drug Delivery
WO2011112999A2 (en) * 2010-03-12 2011-09-15 The Regents Of The University Of California Lipid-peptide-polymer conjugates and nanoparticles thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2326893T3 (es) 1998-05-27 2009-10-21 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
WO2003022250A2 (en) * 2001-09-10 2003-03-20 Celator Technologies Inc. Unilamellar vesicles stabilized with short chain hydrophilic polymers
CA2724408A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
WO2010114632A2 (en) * 2009-04-03 2010-10-07 University Of Houston Metal nanoparticles functionalized with rationally designed coatings and uses thereof
ES2547698T3 (es) * 2009-12-03 2015-10-08 Jiangsu Hengrui Medicine Co., Ltd. Liposoma de irinotecán o su clorhidrato y método de preparación del mismo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110200527A1 (en) * 2007-11-05 2011-08-18 Shanghai Jiaotong University Peptide Ligand Directed Drug Delivery
WO2011112999A2 (en) * 2010-03-12 2011-09-15 The Regents Of The University Of California Lipid-peptide-polymer conjugates and nanoparticles thereof

Also Published As

Publication number Publication date
JP2015520126A (ja) 2015-07-16
EP2841083A4 (en) 2016-07-13
IL235167A0 (en) 2014-12-31
RU2014144945A (ru) 2016-05-27
MX2014012271A (es) 2015-05-11
WO2013155152A1 (en) 2013-10-17
CN104379158A (zh) 2015-02-25
IN2014DN08781A (enExample) 2015-05-22
JP6426600B2 (ja) 2018-11-21
CA2869984A1 (en) 2013-10-17
KR20140143838A (ko) 2014-12-17
CA2869984C (en) 2021-08-17
JP2018150327A (ja) 2018-09-27
EP2841083A1 (en) 2015-03-04
AU2013245989A1 (en) 2014-10-30
EP2841083B1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
US9044514B2 (en) Lipid-peptide-polymer conjugates and nanoparticles thereof
US10806702B2 (en) Bis-polymer lipid-peptide conjugates and nanoparticles thereof
Accardo et al. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs
Fu et al. Integrin αvβ3-targeted liposomal drug delivery system for enhanced lung cancer therapy
Li et al. LHRH-targeted drug delivery systems for cancer therapy
JP6294456B2 (ja) 修飾されたドセタキセルリポソーム製剤
JP2018150327A (ja) ビス−ポリマー脂質−ペプチド複合体及びそのナノ粒子
CN103269722A (zh) 治疗性和/或诊断性纳米载体的靶向的适体缀合物
KR101224711B1 (ko) 림프관내 화학요법 약물 담체
JP2014527071A (ja) H−ホスホネートによるナノ粒子pegの改変
Wang et al. PEGylated doxorubicin nanoparticles mediated by HN-1 peptide for targeted treatment of oral squamous cell carcinoma
KR20150107894A (ko) Mmp-표적 치료 및/또는 진단 나노담체
US20170165382A1 (en) Nanocarriers for cancer treatment
EP3046586B1 (en) Methods of treatment using bis-polymer lipid-peptide conjugates and nanoparticles thereof
US20140363378A1 (en) Self-assembling molecules that accumulate in acidic tumor microenvironments
US11135301B2 (en) Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
Accardo et al. Naposomes: A new class of peptide-derivatized, target-selective multimodal nanoparticles for imaging and therapeutic applications
WO2020076173A1 (en) Nanodelivery tissue targeting at low systemic exposures and methods thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired